Amgen (AMGN) Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/19/2026

1. KLAR
2. KEYS
3. MRNA
4. PANW
5. HD
6. DVLT
7. MRCY
8. LOW
9. MRK
10. PGR

Go back to Amgen (AMGN) Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
Amgen Inc (NASDAQ: AMGN) Delayed: 441.32 +16.04 (3.77%)
Previous Close $425.28    52 Week High $176.85 
Open $430.24    52 Week Low $133.64 
Day High $441.98    P/E 66.46 
Day Low $429.38    EPS $6.64 
Volume 1,462,202